<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00512876</url>
  </required_header>
  <id_info>
    <org_study_id>WRAMC WU# 07-23022</org_study_id>
    <nct_id>NCT00512876</nct_id>
  </id_info>
  <brief_title>Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization</brief_title>
  <official_title>Effectiveness and Safety of Topical Bevacizumab (Avastin) for Treatment of Corneal Neovascularization</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Walter Reed Army Medical Center</agency>
      <agency_class>U.S. Fed</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts Eye and Ear Infirmary</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Walter Reed Army Medical Center</source>
  <brief_summary>
    <textblock>
      Purpose: To determine the efficacy and safety of one commonly used VEGF inhibitor,&#xD;
      bevacizumab (Avastin, Genentech), as a topical agent for the treatment of corneal&#xD;
      neovascularization.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Ocular and Systemic)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Size and Extent of Corneal Neovascularization</measure>
    <time_frame>24 weeks</time_frame>
    <description>computerized image analysis of the corneal photographs were used to measure the change in size and extent of corneal neovascularization from baseline.</description>
  </secondary_outcome>
  <enrollment type="Actual">24</enrollment>
  <condition>Corneal Neovascularization</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (Avastin)</intervention_name>
    <description>Bevacizumab 10mg/mL 1 drop BID x 3 weeks</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  male or female, at least 18 years of age&#xD;
&#xD;
          -  clinically stable corneal neovascularization&#xD;
&#xD;
          -  superficial or deep corneal neovascularization that extends farther than 2mm from the&#xD;
             limbus&#xD;
&#xD;
          -  ability to understand and provide informed consent to participate in this study and&#xD;
             willingness to follow study instructions and likely to complete all required visits.&#xD;
&#xD;
        Clinical stability - all of the following criterial should be excluded before a corneal&#xD;
        neovascularization can be regarded as clinically stable:&#xD;
&#xD;
          -  current or recent (&lt;3 months) episode of corneal and ocular surface infection&#xD;
             (bacterial, viral, fungal, or acanthamoebal)&#xD;
&#xD;
          -  recent (&lt;3 months) ocular surgery, including cataract surgery, and/or laser of any&#xD;
             type in the study eye&#xD;
&#xD;
          -  recent (&lt;6 months) full thickness or lamellar keratoplasty&#xD;
&#xD;
          -  recent (&lt;6 months) ocular surface reconstruction, limbal auto or allograft stem cell&#xD;
             transplantation, or amniotic membrane transplantation&#xD;
&#xD;
          -  current or recent (&lt;3 months) use of contact lens or plan to use contact lens&#xD;
             (excluding bandage contact lens)&#xD;
&#xD;
          -  current or recent (&lt;3 months) persistent corneal epithelial defect (of at leat 14 days&#xD;
             duration) measuring more than 1mm2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  current or recent (&lt;1 month) systemic corticosteroid therapy or periocular&#xD;
             corticosteroid injections to the study eye&#xD;
&#xD;
          -  current or recent (&lt;3 months) intravitreal durg injection to the study eye.&#xD;
&#xD;
          -  recent (&lt;1 month) change in dose and frequency of topical steroids and/or&#xD;
             non-steroidal anti-inflammatory agents&#xD;
&#xD;
          -  uncontrolled hypertension defined as systolic blood pressure &gt;150 mmHg or diastolic&#xD;
             blood pressure of &gt;90 mmHg&#xD;
&#xD;
          -  history of a thromboembolic event, including myocardial infarction or cerebral&#xD;
             vascular accident&#xD;
&#xD;
          -  patients age 75 or older&#xD;
&#xD;
          -  history of renal abnormalities&#xD;
&#xD;
          -  recent (&lt;3 months) or planned surgery&#xD;
&#xD;
          -  history of coagulation abnormalities, including end stage liver disease or current&#xD;
             anticoagulation medication other than aspirin (warfarin, heparin, enoxaparin or&#xD;
             similar anticoagulant agent)&#xD;
&#xD;
          -  all female patients of childbearing potential will be excluded. A female is considered&#xD;
             to be of childbearing potential unless she is postmenopausal and without menses for 12&#xD;
             months or without a uterus and/or both ovaries.&#xD;
&#xD;
          -  any condition (including language barrier) that precludes patient's ability to comply&#xD;
             with study requirements including completion of study.&#xD;
&#xD;
          -  any condition that precludes the patient's ability or an assisting family member's&#xD;
             ability to apply the medication drops or to sustain five minutes of pressure on the&#xD;
             lacrimal ducts after drop application.&#xD;
&#xD;
          -  concurrent enrollment in another clinical investigation medicinal product or device&#xD;
             study is prohibited.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael J Mines, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Walter Reed Army Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Walter Reed Army Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20307</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <study_first_submitted>August 6, 2007</study_first_submitted>
  <study_first_submitted_qc>August 6, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2007</study_first_posted>
  <results_first_submitted>May 15, 2013</results_first_submitted>
  <results_first_submitted_qc>May 15, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 3, 2013</results_first_posted>
  <last_update_submitted>July 3, 2013</last_update_submitted>
  <last_update_submitted_qc>July 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Walter Reed Army Medical Center</investigator_affiliation>
    <investigator_full_name>Michael J. Mines, MD</investigator_full_name>
    <investigator_title>Research Director, Ophthalmology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Corneal Neovascularization</mesh_term>
    <mesh_term>Neovascularization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were recruited from the Ophthalmology Service at Walter Reed Army Medical Center, Washington DC from August 2007 to January 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Topical Avastin 1.0%</title>
          <description>Each participant received topical Avastin to be applied to the affected eye either 2 or 4 times daily over a period of 3 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Topical Avastin 1.0%</title>
          <description>Each participant received topical Avastin to be applied to the affected eye either 2 or 4 times daily over a period of 3 weeks</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.3" spread="3.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events (Ocular and Systemic)</title>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Avastin 1.0%</title>
            <description>Each participant received topical Avastin to be applied to the affected eye either 2 or 4 times daily over a period of 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events (Ocular and Systemic)</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Size and Extent of Corneal Neovascularization</title>
        <description>computerized image analysis of the corneal photographs were used to measure the change in size and extent of corneal neovascularization from baseline.</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Topical Avastin 1.0%</title>
            <description>Each participant received topical Avastin to be applied to the affected eye either 2 or 4 times daily over a period of 3 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Size and Extent of Corneal Neovascularization</title>
          <description>computerized image analysis of the corneal photographs were used to measure the change in size and extent of corneal neovascularization from baseline.</description>
          <units>percentage change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9" spread="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Topical Avastin 1.0%</title>
          <description>Each participant received topical Avastin to be applied to the affected eye</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>All materials that reflects the WRAMC affiliation must be approved and properly cleared before the material is submitted for public dissemination and publication. All publications whereby WRAMC is cited in the bylines will state on the cover page the following sample disclaimer: &quot;The views expressed in this [article, book chapter, speech, presentation, etc.] are those of the author(s) and do not reflect the official policy of the Department of Army, Department of Defense, or U.S. Government.&quot;</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Principal Investigator</name_or_title>
      <organization>U.S. Army Warfighter Refractive Surgery Research Center</organization>
      <phone>571-231-1600</phone>
      <email>rose.sia@us.army.mil</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

